Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.96 - $1.26 $10,263 - $13,470
-10,691 Reduced 32.12%
22,590 $17,000
Q2 2022

Oct 27, 2022

SELL
$1.16 - $1.88 $16,647 - $26,979
-14,351 Reduced 30.13%
33,281 $39,000
Q2 2022

Aug 15, 2022

SELL
$1.16 - $1.88 $16,647 - $26,979
-14,351 Reduced 30.13%
33,281 $39,000
Q1 2022

Oct 27, 2022

BUY
$1.15 - $2.34 $16,503 - $33,581
14,351 Added 43.12%
47,632 $79,000
Q1 2022

May 13, 2022

BUY
$1.15 - $2.34 $4,610 - $9,381
4,009 Added 9.19%
47,632 $79,000
Q4 2021

Feb 14, 2022

SELL
$1.48 - $2.92 $2,843 - $5,609
-1,921 Reduced 4.22%
43,623 $103,000
Q3 2021

Nov 15, 2021

BUY
$2.15 - $3.44 $97,919 - $156,671
45,544 New
45,544 $100,000

About BiondVax Pharmaceuticals Ltd.


  • Ticker BVXV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,678,800
  • Market Cap $12M
  • Description
  • BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Götting...
More about BVXV
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.